Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.14.5 extracted from

  • Rosenstock, J.; Foley, J.E.; Rendell, M.; Landin-Olsson, M.; Holst, J.J.; Deacon, C.F.; Rochotte, E.; Baron, M.A.
    Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance (2008), Diabetes Care, 31, 30-35.
    View publication on PubMed

Application

Application Comment Organism
medicine in pre-diabetic subjects, a 12-week treatment with vildagliptin markedly increases postmeal levels of active glucagon-like peptide 1 and gastric inhibitory polypeptide, improves both alpha- and beta-cell function, decreases postprandial hyperglycemia and decreases A1C levels. Vildagliptin is well tolerated and weight neutral and does not cause hypoglycemia Homo sapiens

Inhibitors

Inhibitors Comment Organism Structure
vildagliptin in pre-diabetic subjects, a 12-week treatment with vildagliptin markedly increases postmeal levels of active glucagon-like peptide 1 and gastric inhibitory polypeptide, improves both alpha- and beta-cell function, decreases postprandial hyperhlycemia and decreases A1C levels. Vildagliptin is well tolerated and weight neutral and does not cause hypoglycemia Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
glucagon-like peptide 1 + H2O
-
Homo sapiens ?
-
?